Nearly one in three clinical research sites, 31% according to WCG’s 2026 Clinical Research Site Challenges Report, say that missed items and document inconsistencies during start-up force modifications that push their timelines back. That figure is striking because the work triggering those delays is largely redundant: sites re-entering data already captured elsewhere, reconciling contracts against protocols that have quietly diverged, chasing discrepancies that a single shared document should have prevented. The cost is not just administrative friction. It is activation time, and activation time is patient access time.
The scale of that cost has an industry reference point. A 2018 benchmarking survey across 61 cancer center members found a median trial activation time of 167 days, nearly double the 90-day target the National Cancer Institute recommends. WCG’s site challenges report, drawing on responses from clinical research professionals across the industry, suggests those structural problems have not resolved: complexity is steeper, not flatter.
WCG’s response is the Study Intelligence Hub, which pulls study and contract data into a source-verified, AI-assisted reference that site teams query instead of rebuilding from scratch each time. The proposition is straightforward: if discrepancies are caught before they produce an amendment, the modification never happens, and the timeline holds. The FDA’s December 2024 draft guidance on protocol deviation documentation tightens the documentation burden sites already carry, which makes early-stage accuracy more consequential, not less.
What makes this worth watching is not the tool itself but the category it represents. Site enablement platforms that consolidate start-up intelligence are a direct bet that the activation bottleneck is an information-organization problem, not simply a negotiation or regulatory one. If WCG’s data holds across the broader site population, the question for sponsors evaluating site selection is whether a site’s activation infrastructure reduces the probability of a modification, because that is where weeks disappear.
Source link: https://www.wcgclinical.com/insights/repeated-work-delayed-starts-the-hidden-cost-of-study-activation/
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
